At the recent Association of Women in Rheumatology annual conference, AWIR and ACR leaders discussed advocacy’s important role in supporting equitable rheumatologic care.
Latest News
Lowest Price, Highest Risk? New Drug Policy’s Potential Effect on Rheumatology
On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.
Rheumatology Could Face New Challenges Under Drug Tariff Reforms
A 15% tariff on all European Union exports, including pharmaceuticals, went into effect on Aug. 7. The tariff could impact the cost of providing care, patient access to therapies and drug research and development.
DOJ Tightens Oversight of DEI Programs: Implications for Rheumatology
A July 30 memo from Attorney General Pam Bondi clarifies how federal anti-discrimination laws apply to programs that might involve discriminatory practices, including those that fall under the umbrella of diversity, equity and inclusion.
Countdown to ACR Convergence 2025: Early Registration Ends Aug. 21
Learn about the registration options and add-on opportunities associated with ACR Convergence 2025, to be held Oct. 24–29 in Chicago, Ill.
The What, Why & How of MIPS Exception Applications
Practices that have experienced extreme circumstances—including wildfires or flooding—can apply for exceptions for Quality Payment Program reporting. Applications for 2025 are open through Dec. 31.
